Purification, Characterization, and Immunogenicity of the Refolded Ectodomain of the Plasmodium falciparum Apical Membrane Antigen 1 Expressed in Escherichia coli
Open Access
- 1 June 2002
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 70 (6) , 3101-3110
- https://doi.org/10.1128/iai.70.6.3101-3110.2002
Abstract
The apical membrane antigen 1 (AMA1) has emerged as a promising vaccine candidate against malaria. Advanced evaluation of its protective efficacy in humans requires the production of highly purified and correctly folded protein. We describe here a process for the expression, fermentation, refolding, and purification of the recombinant ectodomain of AMA1 (amino acids 83 Gly to 531 Glu ) of Plasmodium falciparum (3D7) produced in Escherichia coli. A synthetic gene containing an E. coli codon bias was cloned into a modified pET32 plasmid, and the recombinant protein was produced by using a redox-modified E. coli strain, Origami (DE3). A purification process was developed that included Sarkosyl extraction followed by affinity purification on a Ni-nitrilotriacetic acid column. The recombinant AMA1 was refolded in the presence of reduced and oxidized glutathione and further purified by using two ion-exchange chromatographic steps. The final product, designated AMA1/E, was homogeneous, monomeric, and >99% pure and had low endotoxin content and low host cell contamination. Analysis of AMA1/E showed that it had the predicted primary sequence, and tertiary structure analysis confirmed its compact disulfide-bonded nature. Rabbit antibodies made to the protein recognized the native parasite AMA1 and inhibited the growth of the P. falciparum homologous 3D7 clone in an in vitro assay. Reduction-sensitive epitopes on AMA1/E were shown to be necessary for the production of inhibitory anti-AMA1 antibodies. AMA1/E was recognized by a conformation-dependent, growth-inhibitory monoclonal antibody, 4G2dc1. The process described here was successfully scaled up to produce AMA1/E protein under GMP conditions, and the product was found to induce highly inhibitory antibodies in rabbits.Keywords
This publication has 30 references indexed in Scilit:
- Purification, Characterization, and Immunogenicity of a Disulfide Cross-Linked Plasmodium vivax Vaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed in Escherichia coliInfection and Immunity, 2001
- Proteolytic Processing and Primary Structure ofPlasmodium falciparum Apical Membrane Antigen-1Journal of Biological Chemistry, 2001
- Specificity of the Protective Antibody Response to Apical Membrane Antigen 1Infection and Immunity, 2001
- Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasionMolecular and Biochemical Parasitology, 2000
- Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoelii YM Blood-Stage InfectionInfection and Immunity, 2000
- The Disulfide Bond Structure of Plasmodium Apical Membrane Antigen-1Journal of Biological Chemistry, 1996
- Sequence analysis of the apical membrane antigen-1 genes (ama-1) of Plasmodium yoelii yoelii and Plasmodium bergheiMolecular and Biochemical Parasitology, 1996
- Sequence analysis of apical membrane antigen 1 (AMA-1) of Plasmodium cynomolgi bastianelliMolecular and Biochemical Parasitology, 1995
- Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoitesMolecular and Biochemical Parasitology, 1994
- Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigenParasite Immunology, 1988